- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04545190
RibOSE - Glucose and Resistance Exercise Training (RibOSE)
RibOSE - Effects of Glucose Ingestion During Resistance Exercise Training on Ribosomal Biogenesis in Skeletal Muscle
Study Overview
Detailed Description
Muscular responses to resistance training vary extensively between humans, with many showing impaired growth. In such individuals, cellular plasticity is compromised, leading to reduced functional and health-beneficial outcomes of training. While this is likely due to a range of determinants, including epigenetic, genetic and physiological variables, recent studies suggest that it involves reduced ability to produce novel ribosomes in response to training. This eventually leads to less pronounced increases in protein synthesis, and thus decreased growth rates, and makes ribosomal content in muscle a potential proxy marker for training-associated muscle hypertrophy.
In a recent study, the investigators showed that increased resistance training volume was associated with more pronounced muscle growth, a trait that was associated with increased ribosomal biogenesis. Despite this, ~50 % of the participants did not exhibit true beneficial effects of increased training volume, which in turn coincided with reduced abilities to accumulate ribosomes. In such individuals, other means are likely necessary to circumvent the negative influence of genetic and epigenetic predispositions on muscle plasticity. Nutrient supplementation stand out as a potential therapy. However, at present, knowledge with regard to this perspective is limited to a selected few nutrients, with protein ingestion being the best studied potential adjuvant, for which adequate intake seems to be essential for achieving optimal muscle growth, potentially being interconnected with ribosomal synthesis. For other nutrients, such as glucose, little is know about their importance for muscle plasticity and ribosomal biogenesis.
In cell types such as cultivated kidney cells, exposure to high levels of glucose is an efficient mean to increase ribosomal biogenesis (and growth rates). This suggests that glucose is an important signaling molecule for increasing ribosomal production per se, perhaps acting as a ligand for signaling proteins or by acting to increase energy availability. In the human body (as opposed to cultured cells), glucose may also exert growth-stimulating effects by increasing insulin levels in blood. Overall, it thus seems plausible that glucose intake during resistance training may stimulate ribosomal biogenesis, in turn having beneficial effects for protein synthesis and muscle plasticity, perhaps acting in an additive manner to protein supplementation. At present, we do not know if this is the case, though studies have suggested that glucose ingestion during acute resistance training sessions may reduce training-induced muscle damage without affecting within-session work output (i.e. volume). This lack of knowledge is surprising given the long-standing appreciation of the beneficial effects of glucose intake for endurance performance, acting to delay muscular fatigue.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Lillehammer, Norway
- Inland Norway University of Applied Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Non-smoking
- Moderately trained (i.e. having performed 2-8 resistance training sessions per 14 days for the last six months)
Exclusion Criteria:
- Not able to understand Norwegian
- Unstable cardiovascular disease
- Illness or injury contradicting heavy strength training
- Disabling musculoskeletal disease
- Serious mental illness
- Allergy to local anaesthesia
- Impaired glucose tolerance
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Glucose
Glucose will be ingested at three time points during resistance training (RT): 30 min prior to RT (30 g glucose mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (30 g, 300 ml), and immediately after completion of training (30 g, 300 ml). Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g). Placebo will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 100 mg Stevia powder mixed with 3 x 300 ml sugar-free Fun light lemonade. (The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. During this time frame, participants will ingest glucose and protein supplements only) |
To investigate the effects of glucose intake during resistance training on muscle biological adaptations
|
|
Placebo Comparator: Placebo
Placebo will be ingested at three time points during resistance training (RT): 30 min prior to RT (100 mg Stevia powder mixed with 300 ml sugar-free Fun light lemonade), immediately prior to RT (100 mg, 300 ml), and immediately after completion of training (100 mg, 300 ml). Protein supplement will be ingested at two time points: 2 hours prior to RT (e.g. at 0700 hrs, 25 g) and immediately after completion of training (25 g). Glucose will be ingested during the afternoon (i.e. not during training; between 1800 hrs and 1900 hrs): 3 x 30 g glucose mixed with 3 x 300 ml sugar-free Fun light lemonade. (The dietary intervention spans from 2200 hrs on the evening prior to RT sessions to ~2.5 hrs after completion of RT. I.e.: during this period, participants will ingest placebo and protein supplements only) |
To investigate the effects of glucose intake during resistance training on muscle biological adaptations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Total RNA in muscle tissue
Time Frame: Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
Total RNA content in m. vastus lateralis (ug per mg tissue)
|
Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Ribosomal RNA in skeletal muscle
Time Frame: Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
Abundances of ribosomal RNA species in m. vastus lateralis measured using qPCR
|
Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
|
Protein in skeletal muscle
Time Frame: Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
Abundances of protein species in m. vastus lateralis measured using Western blotting (e.g.
ECM proteins)
|
Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
|
Gene expression in skeletal muscle
Time Frame: Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
Abundances of mRNA species in m. vastus lateralis measured using qPCR
|
Before the intervention and immediately after the intervention (i.e. after 5 training sessions of each leg)
|
|
Muscle fractional synthesis rate
Time Frame: Immediately after the intervention
|
Protein synthesis rate measured using heavy water (deuterium) and chromatography/spectrometry
|
Immediately after the intervention
|
|
Glucose in blood, after glucose/placebo intake
Time Frame: Immediately before glucose/placebo intake and 30 min, 45 min, 60 min and 195 min after initial glucose/placebo intake
|
Glucose concentrations in blood (area under the curve), measured before and after intake of glucose/placebo on the two final days of the intervention (one day = glucose; one day = placebo)
|
Immediately before glucose/placebo intake and 30 min, 45 min, 60 min and 195 min after initial glucose/placebo intake
|
|
Glucose in blood (after protein intake)
Time Frame: Immediately before protein intake and 45 min and 90 min after protein intake
|
Glucose concentrations in blood (area under the curve), measured before and after intake of protein on the two final days of the intervention
|
Immediately before protein intake and 45 min and 90 min after protein intake
|
|
Hormone concentrations in blood (after glucose/placebo intake)
Time Frame: Immediately before glucose/placebo intake and 30 min and 60 min after the initial glucose/placebo intake
|
Abundances of insulin, c-peptide, testosterone, growth hormone, cortisol and inflammatory markers in blood (area under the curve), measured before and after intake of glucose/placebo on the two final days of the intervention (one day = glucose; one day = placebo)
|
Immediately before glucose/placebo intake and 30 min and 60 min after the initial glucose/placebo intake
|
|
Hormone concentrations in blood (after protein intake)
Time Frame: Immediately before protein intake and 90 min after protein intake
|
Abundances of insulin, c-peptide, testosterone, growth hormone, cortisol and inflammatory markers in blood, measured after intake of protein on the two final days of the intervention
|
Immediately before protein intake and 90 min after protein intake
|
|
Unilateral lower body isokinetic muscle strength (during the intervention)
Time Frame: Before the intervention and after the second, fourth and sixth training session
|
The ability of the knee extensors to exert maximal force during isokinetic movements (recovery/strength), measured before the intervention and at three time points during the intervention (~24 hours after training sessions)
|
Before the intervention and after the second, fourth and sixth training session
|
|
Unilateral lower body isokinetic muscle strength (last days of the intervention)
Time Frame: Before the last training session and 30 min, 120 min and 24 hours after the last training session
|
The ability of the knee extensors to exert maximal force during isokinetic movements (recovery/strength), measured before and at three time points after the last two training sessions (one day = glucose; one day = placebo)
|
Before the last training session and 30 min, 120 min and 24 hours after the last training session
|
|
Unilateral lower body isometric muscle strength (during the intervention)
Time Frame: Before the intervention and after the second, fourth and sixth training session
|
The ability of the knee extensors to exert maximal force during isometric actions (recovery/strength), measured before the intervention and at three time points during the intervention (~24 hours after training sessions)
|
Before the intervention and after the second, fourth and sixth training session
|
|
Unilateral lower body isometric muscle strength (last days of the intervention)
Time Frame: Before the last training session and 30 min, 120 min and 24 hours after the last training session
|
The ability of the knee extensors to exert maximal force during isometric actions (recovery/strength), measured before and at three time points after the last two training sessions (one day = glucose; one day = placebo)
|
Before the last training session and 30 min, 120 min and 24 hours after the last training session
|
|
Perceived muscle soreness (during the intervention)
Time Frame: Before the intervention and 24 hours after each training session
|
Muscular soreness measured before the intervention and at three time points during the intervention (~24 hours after training sessions) using a VAS-scale from 0 to 10 (0 = no soreness; 10 = maximal soreness)
|
Before the intervention and 24 hours after each training session
|
|
Perceived feeling of the legs (during the intervention)
Time Frame: 30 min after each training session
|
Feeling of the legs measured immediately after each training session using a 9-point scale (1 = very very good, 9 = very very heavy)
|
30 min after each training session
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Training diary
Time Frame: During each training session of the intervention
|
Training volume (total kg lifted) during each day of the intervention
|
During each training session of the intervention
|
|
Body mass composition
Time Frame: Prior to the intervention
|
Body mass composition measured using DXA
|
Prior to the intervention
|
|
Dietary registration
Time Frame: During each day of the intervention
|
Nutritional intake during each day of the intervention, tracked using MyFitnessPal
|
During each day of the intervention
|
|
Unilateral lower body maximal strength
Time Frame: Before the intervention
|
The ability of muscles of the lower body to exert maximal force during dynamic movements
|
Before the intervention
|
|
Blind test glucose vs placebo comparators
Time Frame: Immediately after the intervention
|
The ability to discriminate between glucose and placebo beverages, tested after the training intervention using a blinded randomized design: each participant will ingest six beverages (3 x glucose and 3 x placebo) and will be asked to identify theam as either glucose or placebo.
The "ability to discriminate" will be determined based on analyses of the full study population
|
Immediately after the intervention
|
|
Deuterium in spit
Time Frame: On each day of the intervention
|
Deuterium levels in spit on each day during the intervention measured using chromatography/spectrometry (sampled prior to each training session)
|
On each day of the intervention
|
|
Fasting blood glucose
Time Frame: Before the intervention and immediately after the intervention
|
Fasting blood glucose measured in serum, measured before the intervention and prior to training on the last two days of the intervention
|
Before the intervention and immediately after the intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Stian Ellefsen, PhD, Inland Norway University of Applied Sciences
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Trainome#024_2020
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
University of Vermont Medical CenterAvocado Nutrition CenterRecruitingHealthy | Healthy Volunteers | Healthy Subjects | Healthy Volunteer | Healthy Adult | Healthy Volunteers Only | Healthy Male and Female Subjects | Healthy Non-smokersUnited States
-
Dragonfly TherapeuticsRecruitingHealthy | Healthy Participants | Healthy Adult Females | Volunteer | Healthy Adult MaleAustralia
-
University of PalermoCompletedHealthy | Healthy Volunteers | Healthy Subjects | Healthy Participants | Static Stretching | Stretch | StretchingItaly
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Umm Al-Qura UniversityActive, not recruitingHealthy | Healthy Participants | Healthy Adult | Healthy Women | Healthy Adult Females | Healthy Adult Participants | Healthy Young Adults | Healthy Adult Female Participants | Healthy Adult Male | Poor Sleep Quality | Healthy (Controls) | Poor Sleeping Quality | Healthy Adult Male Subjects | Health Adult SubjectsSaudi Arabia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
University of PalermoCompletedHealthy Participants | Healthy Adult Participants | Healthy Young AdultsItaly
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
PfizerNot yet recruitingHealthy | Healthy AdultsUnited States
-
Atisama TherapeuticsRecruitingHealthy | Healthy SmokerAustralia
Clinical Trials on Glucose
-
University of Texas Southwestern Medical CenterCompletedSarcoma | Neuroblastoma | Pediatric CancerUnited States
-
Stanford UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Suspended
-
Children's Mercy Hospital Kansas CityWithdrawnType 1 DiabetesUnited States
-
University of Massachusetts, WorcesterRecruitingPregnancy, High Risk | Type 2 Diabetes Treated With InsulinUnited States
-
Glostrup University Hospital, CopenhagenUnknown
-
Makassed General HospitalCompleted
-
Unilever R&DLeiden University Medical CenterCompleted
-
US Department of Veterans AffairsEmory UniversityCompletedType 2 Diabetes Mellitus | Prediabetic StateUnited States